Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1221-1240 of 2,251 trials

Prostate Cancer: Re-treatment with [177Lu]Lu-PSMA

We are studying the effects of re-treating men with metastatic castration-resistant prostate cancer using [177Lu]Lu-PSMA. This trial aims to see if this treatment can help improve survival and quality of life.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Head and Neck Cancer: Cetuximab with Chemotherapy

We are studying a combination of cetuximab and chemotherapy followed by immunotherapy for patients with recurrent or metastatic head and neck cancer. The goal is to see if this treatment improves survival and response rates for those with a specific PD-L1 score.

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Cancer Imaging: [18F]AlF-FAPI-74 PET/CT

We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.

Pancreatic CancerEsophagogastric AdenocarcinomaGastric Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Apixaban in Short Bowel Syndrome Patients

We are studying how the blood levels of apixaban differ in patients with short bowel syndrome who require long-term IV nutrition. This research may help improve treatment strategies for these patients.

Short Bowel Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

Haemophilia A1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOrthopedics and Traumatology

Sleeping through Menopause: Hormone Therapy and Online Sleep Support

We are studying whether hormone therapy and a guided online sleep program can help improve sleep and mood in perimenopausal women. This trial aims to enhance mental health and overall well-being during this transition.

InsomniaClimacteric Symptoms3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsPsychiatry

Neurocritical Patients: Inhalation vs. Intravenous Sedation

We are studying whether inhalation sedation with isoflurane is more effective and safer than conventional intravenous sedation for patients in critical neurological care. This trial will help us understand the best sedation methods for these patients.

Pain ReliefMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Glucothera Plus for Children on Peritoneal Dialysis

We are studying the safety of Glucothera Plus in children receiving peritoneal dialysis. We also want to see if it helps restore L-carnitine levels in these patients.

End-stage Kidney Disease6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

CNS Lymphoma: [90Y]Y-PentixaTher Therapy

We are studying the safety and effectiveness of [90Y]Y-PentixaTher in patients with recurrent or refractory central nervous system lymphoma. This trial aims to find the best dose and understand how the treatment works in the body.

CNS LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Brain Surgery Pain Management: Nerve Block Comparison

We are comparing two types of nerve blocks to see which one helps reduce pain and improve recovery for patients undergoing brain surgery. This study aims to find the best option for managing discomfort during the procedure.

Patients Undergoing Craniotomy for Supratentorial Mass>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Pancreatic Cancer: Digitoxin and Chemotherapy Study

We are exploring whether adding digitoxin to chemotherapy can help improve survival for patients with inoperable pancreatic cancer. The trial also looks at treatment safety and quality of life.

Pancreatic Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

GLM101 for PMM2-CDG: Safety and Effects

We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.

PMM2-CDGEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal Medicine

Advanced Non-Small Cell Lung Cancer: PD-1 Inhibitor with Chemotherapy and Radiation

We are studying whether adding radiation to a PD-1 inhibitor and chemotherapy improves survival and tumor response in patients with advanced non-small cell lung cancer. This trial also looks at side effects and quality of life.

Advanced Non-Small Cell Lung Cancer (NSCLC)3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether adding chemotherapy after surgery or ablation helps improve outcomes for patients with metastatic colorectal cancer compared to just follow-up care.

Metastatic Colorectal CancerConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Burn Treatment in Children: New Skin Graft Study

We are testing a new skin graft made from the child's own cells for treating severe burns in children. The goal is to see if it works better and is safer than the standard skin graft method.

Children with Severe Burns1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatology